UY32938A - Derivados de feniloxadiazol como agentes inhibidores de las pgds - Google Patents

Derivados de feniloxadiazol como agentes inhibidores de las pgds

Info

Publication number
UY32938A
UY32938A UY0001032938A UY32938A UY32938A UY 32938 A UY32938 A UY 32938A UY 0001032938 A UY0001032938 A UY 0001032938A UY 32938 A UY32938 A UY 32938A UY 32938 A UY32938 A UY 32938A
Authority
UY
Uruguay
Prior art keywords
phenyloxadiazol
pgds
derivatives
inhibiting agents
compound
Prior art date
Application number
UY0001032938A
Other languages
English (en)
Inventor
Harpal S Gill
Hillegass Andrea
Lee George
Christopher L Vandeusen
Franz J Weiberth
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32938A publication Critical patent/UY32938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula (I): en la que R1, R2 and R3 son como se definen en la presente memoria, a una composición farma céutica que comprende el compuesto, compuestos in termedios y a un procedimiento para fabricar dich os compuestos, y al uso del compuesto para tratar 10 trastornos inflamatorios y/o alérgicos, particularmente trastornos tales como rinitis alérgica, asma, enfermedad pulmonar obstructiva crónica (C OPD) y degeneración macular relacionada con la ed ad (AMD).
UY0001032938A 2009-10-08 2010-10-08 Derivados de feniloxadiazol como agentes inhibidores de las pgds UY32938A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24969309P 2009-10-08 2009-10-08
FR1056094 2010-07-26

Publications (1)

Publication Number Publication Date
UY32938A true UY32938A (es) 2011-05-31

Family

ID=43606440

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032938A UY32938A (es) 2009-10-08 2010-10-08 Derivados de feniloxadiazol como agentes inhibidores de las pgds

Country Status (21)

Country Link
US (5) US9469627B2 (es)
EP (1) EP2486024B1 (es)
JP (2) JP5753176B2 (es)
KR (1) KR101701135B1 (es)
CN (3) CN107875155A (es)
AR (1) AR078552A1 (es)
AU (1) AU2010303439B2 (es)
BR (1) BR112012007635B1 (es)
CA (1) CA2776242C (es)
DK (1) DK2486024T3 (es)
ES (1) ES2543011T3 (es)
HK (1) HK1173441A1 (es)
IL (1) IL218967A (es)
MA (1) MA33725B1 (es)
MX (1) MX2012003021A (es)
NZ (1) NZ599099A (es)
RU (2) RU2015151129A (es)
SG (1) SG179199A1 (es)
TW (1) TWI508960B (es)
UY (1) UY32938A (es)
WO (1) WO2011044307A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107875155A (zh) * 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2016370779B2 (en) 2015-12-17 2019-07-25 Astex Therapeutics Limited Quinoline-3-carboxamides as H-PGDS inhibitors
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
SI3630738T1 (sl) * 2017-05-22 2024-02-29 Egis Gyogyszergyar Zrt. Postopek za ustvarjanje ozanimoda
WO2018229629A1 (en) 2017-06-13 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
BR112020011889A2 (pt) 2017-12-13 2020-11-24 Glaxosmithkline Intellectual Property Development Limited piridinas fundidas que agem como inibidores de h-pgds
BR112021008976A2 (pt) 2018-11-08 2021-08-03 Glaxosmithkline Intellectual Property Development Limited compostos químicos
EP4169575A4 (en) 2020-06-19 2023-10-25 Sato Pharmaceutical Co., Ltd. CONDENSED RING CONNECTIONS FOR INHIBITING H-PGDS
CA3240926A1 (en) * 2021-12-17 2023-06-22 Sato Pharmaceutical Co., Ltd. Azaindole derivative inhibiting h-pgds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176132A (en) 1989-05-31 1993-01-05 Fisons Plc Medicament inhalation device and formulation
DE10117823A1 (de) * 2001-04-10 2002-10-17 Merck Patent Gmbh Oxalsäurederivate
ATE516277T1 (de) * 2002-03-19 2011-07-15 Ono Pharmaceutical Co Carbonsäureverbindungen und arzneimittel, die diese verbindungen als wirkstoffe enthalten
JP2006511789A (ja) 2002-08-16 2006-04-06 アベンティス・ファーマスーティカルズ・インコーポレイテツド ミクロソームのプロスタグランジンｅ合成酵素または造血系プロスタグランジンｄ合成酵素の活性を低下させる能力に関して化合物または薬剤をアッセイする方法
GB0222023D0 (en) 2002-09-21 2002-10-30 Aventis Pharma Ltd Inhaler
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
TW200538118A (en) * 2004-04-21 2005-12-01 Schering Corp Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
JP5209181B2 (ja) * 2005-03-15 2013-06-12 富士フイルム株式会社 化合物、組成物、位相差板、楕円偏光板および液晶表示装置
TW200720255A (en) 2005-07-13 2007-06-01 Taiho Pharmaceutical Co Ltd Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP2007051121A (ja) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
CN100556905C (zh) * 2005-09-08 2009-11-04 国家南方农药创制中心江苏基地 吡唑酰胺类化合物及其中间体和以该类化合物为活性成分的有害生物防治剂
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
PE20070589A1 (es) 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
WO2008075172A2 (en) 2006-12-19 2008-06-26 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CA2679198C (en) * 2007-02-26 2011-07-12 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2142516B1 (en) 2007-03-30 2012-12-26 Sanofi Pyrimidine hydrazide compounds as pgds inhibitors
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
TW201034675A (en) * 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
US9058931B2 (en) 2009-01-12 2015-06-16 The United States Of America, As Represented By The Secretary Of The Navy Composite electrode structure
CN107875155A (zh) * 2009-10-08 2018-04-06 赛诺菲 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途

Also Published As

Publication number Publication date
WO2011044307A1 (en) 2011-04-14
JP5897186B2 (ja) 2016-03-30
RU2015151129A (ru) 2019-01-15
CN102666508A (zh) 2012-09-12
MX2012003021A (es) 2012-04-10
US20190000845A1 (en) 2019-01-03
JP2015178516A (ja) 2015-10-08
DK2486024T3 (en) 2015-07-27
JP2013507376A (ja) 2013-03-04
US20230190747A1 (en) 2023-06-22
EP2486024B1 (en) 2015-04-22
TW201127835A (en) 2011-08-16
CA2776242C (en) 2014-09-02
KR20120094910A (ko) 2012-08-27
RU2572608C2 (ru) 2016-01-20
SG179199A1 (en) 2012-04-27
US20120190695A1 (en) 2012-07-26
CN107875155A (zh) 2018-04-06
CN106943407A (zh) 2017-07-14
AU2010303439B2 (en) 2015-10-29
RU2015151129A3 (es) 2019-07-17
RU2012118756A (ru) 2013-11-20
AU2010303439A1 (en) 2012-04-26
TWI508960B (zh) 2015-11-21
AR078552A1 (es) 2011-11-16
NZ599099A (en) 2013-05-31
IL218967A (en) 2015-05-31
BR112012007635A2 (pt) 2017-06-20
US20170231990A1 (en) 2017-08-17
US9469627B2 (en) 2016-10-18
US9937175B2 (en) 2018-04-10
US20190262338A1 (en) 2019-08-29
CA2776242A1 (en) 2011-04-14
IL218967A0 (en) 2012-07-31
ES2543011T3 (es) 2015-08-13
KR101701135B1 (ko) 2017-02-01
HK1173441A1 (en) 2013-05-16
MA33725B1 (fr) 2012-11-01
JP5753176B2 (ja) 2015-07-22
BR112012007635B1 (pt) 2019-07-09
EP2486024A1 (en) 2012-08-15

Similar Documents

Publication Publication Date Title
UY32938A (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
UY29840A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CO7131358A2 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CO7131357A2 (es) Compuestos de n-ariltriazol como antagonistas de lpar
PA8774101A1 (es) Compuesto de pirmidina
CU20160167A7 (es) Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias
ECSP088741A (es) Derivados de benzotriazol como agonistas del adrenoreceptor beta2
CL2014000630A1 (es) Una composicion que comprende 1) un compuesto derivado de nucleosido denominado como compuesto 10 y 2) un compuesto derivado de acido 5-tiofeno-2-carboxilico denominado como compuesto 5 o un compuesto derivado del ester metilico del acido carbamico denominado como compuesto 6; y su uso para el tratamiento profilactico o terapeutico de una infeccion por vhc.
CR20130339A (es) Nuevos derivados heterocíclicos y su uso en el tratamiento de desordenes neurológicos
ECSP11010754A (es) Derivados de triazol útiles para el tratamiento de enfermedades
UY34960A (es) Dihidropiridona p1 como inhibidores del factor xia
UY34959A (es) Dihidropiridona p1 como inhibidores del factor xia
CO6690816A2 (es) Derivados de quinazolin-4(3h)-ona utilizados como inhibidores de pi3 cinasa
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CL2020002939A1 (es) Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas
CO7160077A2 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
UY31204A1 (es) Derivados de macrolactona
AR080527A1 (es) Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2
CR11666A (es) Farmacoforos duales- antagonistas muscarinicos pdea
ECSP099328A (es) Análogos de pirazol

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190219